A spinal cord injury happens twice. The first time is mechanical, in an instant. The second time unfolds over the following hours and days as damaged tissue triggers apoptosis, oxidative stress and an inflammatory response that kills cells the original impact spared. That second phase, the secondary injury, is what almost every experimental treatment in this field is aimed at, and it is the reason a compound whose main action is protein-folding support has been tested here at all.
This site covers TUDCA and neuroprotection in general and the ALS trials specifically, along with tissue-specific preclinical literatures such as cochlear protection and hearing loss. Spinal cord injury is a separate literature with its own models, its own endpoints and, as of 2026, its own systematic review. The short version is that the pooled rodent data look good at the two-week mark, that the one study which followed animals for six weeks found the benefit did not last, and that nobody has given TUDCA to a person with a spinal cord injury in a published trial.
Key Takeaways
- A 2026 systematic review and meta-analysis pooled 14 preclinical in vivo studies and found motor function on the BBB score significantly improved at day 14 (weighted mean difference 3.11, 95% CI 1.84 to 4.37, p less than 0.0001)[1].
- In that same review, subgroup analysis suggested a more pronounced effect in female animals (weighted mean difference 3.76, 2.51 to 5.10)[1].
- The first published spinal cord study, in 2008, gave 30 rats 200 mg/kg intraperitoneally one minute after a weight-drop injury and cut apoptotic cell counts roughly in half at 24 hours (4.52 +/- 0.30 down to 2.31 +/- 0.24)[2].
- A 2021 mouse study using 200 mg/kg by gavage daily for 14 days reported less oxidative stress, inflammation and apoptosis, plus axon regeneration and remyelination at the lesion site[3].
- A 2022 rat contusion study that followed animals for six weeks found the motor benefit was transient. No significant difference from vehicle remained 1 to 6 weeks after the lesion, and the authors wrote that their data do not support the use of TUDCA as a treatment for spinal cord injury[4].
- There is no human trial of TUDCA for spinal cord injury.
Why a Chemical Chaperone Is Tested Here at All
Apoptosis is a central event in secondary injury, and TUDCA is an anti-apoptotic bile acid that suppresses endoplasmic reticulum stress. A 2018 mouse study made that link explicit: intraperitoneal TUDCA reduced lesion area and apoptotic ratios after traumatic injury, and the ER stress markers Grp78, Erdj4 and CHOP were all attenuated by treatment[5]. The same study found levels of CIBZ, a gene the authors describe as a novel therapeutic target in this setting, were specifically up-regulated[5].
A 2022 experiment took the mechanism in a different direction. Rat spinal cord neurons were cultured, injured mechanically, then treated with TUDCA across a range of concentrations. Survival was around 50 percent at the injury setting used, and rose to roughly 80 percent at 4 mmol/L TUDCA. Electron microscopy showed the number of autophagic lysosomes increased significantly in the treated group, alongside changes in Beclin-1 and LC3 II/I, which the authors read as autophagy being part of the protective mechanism rather than a sign of damage[6].
What the Pooled Animal Data Actually Say
The 2026 systematic review is the most useful single document in this literature. It was reported to PRISMA 2020, searched PubMed, Embase, Web of Science, CNKI and SinoMed from inception to May 2025 without language restriction, collected grey literature, and had two reviewers independently assess risk of bias with the SYRCLE tool. Fourteen studies met inclusion, and over half rated low risk of bias on at least five items[1].
The headline result is the BBB locomotor score at day 14, where TUDCA-treated animals scored a weighted mean 3.11 points higher. The inclined plane test and TUNEL staining pointed the same way. The authors also ran network pharmacology with molecular docking to propose a mechanism[1].
Two caveats belong next to that number rather than underneath it. A preclinical meta-analysis pools small studies from labs with an interest in a positive result, and the SYRCLE assessment here is reassuring rather than clean. And a 3-point BBB improvement in a rat is a measurement of rat hindlimb movement, not a statement about human walking.
How the Individual Studies Were Actually Dosed
Reading the dosing is what separates this literature from anything a person could replicate. The 2008 study produced trauma at T8 to T10 by the Allen weight-drop technique and injected 200 mg/kg intraperitoneally one minute after the injury, then assessed hind-limb function with the inclined plane technique and a modified Tarlov scale at 24 hours, 3 days and 5 days[2]. The 2021 study used a pneumatic impact device at T9 to T10 and gave 200 mg/kg by gavage daily for 14 days, having first shown that TUDCA protected primary cortical neurons from hydrogen peroxide in culture[3].
A 2020 study went further and built the drug into the delivery. The authors soaked a hydrogel in TUDCA solution and injected the gel into the injury site. Motor function and lesion size improved against saline, pro-inflammatory cytokines fell, and phosphorylation of ERK and JNK in the MAPK pathway was suppressed. Notably the gel outperformed plain TUDCA and plain gel given separately[7].
So the experimental picture is an injection or a gavage or an implanted gel, at 200 mg/kg, starting within minutes of a controlled injury. None of those three variables resembles a capsule taken by mouth days later, and the absorption question is bypassed entirely by two of the three routes.
The Study That Kept Watching
Most of this work stops at 14 days, which is exactly where the meta-analysis found its effect. One 2022 study did not stop there, and it is the single most important paper on this page.
Rats received a contusion injury at T9 and were treated with intraperitoneal TUDCA, either alone or combined with a single injection of human bone marrow-derived stromal cells into the cisterna magna. Recovery of motor function was assessed over six weeks. Biochemical and histological analysis confirmed that TUDCA was doing something real: its anti-inflammatory activity in the injured cord was verified[4].
The functional results were another matter. Treatment improved recovery of autonomic bladder control and had a positive effect on motor function in the subacute phase, but the benefits were only transient, and no significant differences between vehicle and TUDCA-treated animals remained 1 to 6 weeks after the lesion. Combining TUDCA with the stromal cells added nothing over the cells alone. The authors concluded plainly that their data do not support the use of TUDCA as a treatment of spinal cord injury[4].
That is not a contradiction of the meta-analysis so much as a warning about what it measured. An anti-inflammatory effect that is genuinely present at two weeks and a functional benefit that persists at six weeks are different claims, and only one of them has been tested repeatedly.
What This Cannot Tell a Person
There is no randomised trial, no open-label trial and no case series of TUDCA for spinal cord injury in humans. The closest humans have come to taking TUDCA at any scale is elsewhere: a combination product with sodium phenylbutyrate tested in ALS[8], and a randomised double-blind trial in progressive multiple sclerosis where 2 g/day for 16 weeks was safe and well tolerated but produced no significant differences in clinical or fluid biomarker outcomes[9]. Those tell you something useful about tolerability at a real human dose. They tell you nothing about spinal cords.
Acute spinal cord injury is a surgical and critical-care emergency where timing is measured in hours and the interventions with human outcome data are decompression, blood pressure management and rehabilitation. Nothing on this page is medical advice, and anyone weighing a supplement alongside that care should be reading the safety profile and talking to the treating team rather than to a product page.
Frequently Asked Questions
Does TUDCA help spinal cord injury?
In rodents, short-term, the pooled evidence says yes: 14 studies gave a weighted mean BBB motor improvement of 3.11 points at day 14[1]. In the one study that followed animals for six weeks, the benefit did not persist and the authors advised against the use of TUDCA for this indication[4]. In humans, unknown, because it has never been tested.
What doses were used in the animal studies?
200 mg/kg is the recurring figure, given intraperitoneally in the 2008 rat study[2] and by daily gavage in the 2021 mouse study[3]. Cultured spinal cord neurons responded best at 4 mmol/L[6]. These are experimental doses and routes, not supplement doses.
Why do the studies disagree?
Mostly follow-up length. The positive pooled result is anchored at day 14, and the negative result comes from the study that carried on to week six[4][1]. Model, species, sex and administration route also vary, and the 2026 review found a larger effect in female animals than male[1].
Is the mechanism the same as in the ALS work?
Partly. Both rest on suppressing endoplasmic reticulum stress and apoptosis, and the spinal cord studies document that directly through Grp78, Erdj4 and CHOP[5]. The injury context is different though: traumatic injury adds an acute inflammatory and oxidative cascade that a slow degenerative disease does not have. The neuroprotection overview covers the shared mechanism in more detail.
References
- The Effect and Potential Pharmacological Mechanism of Tauroursodeoxycholic Acid for Spinal Cord Injury: A Systematic Review and Network Pharmacology. Curr Neuropharmacol (2026).
- Tauroursodeoxycholic acid and secondary damage after spinal cord injury in rats. J Clin Neurosci (2008).
- Tauroursodeoxycholic acid alleviates secondary injury in spinal cord injury mice by reducing oxidative stress, apoptosis, and inflammatory response. J Neuroinflammation (2021).
- Tauroursodeoxycholic Acid Reduces Neuroinflammation but Does Not Support Long Term Functional Recovery of Rats with Spinal Cord Injury. Biomedicines (2022).
- Tauroursodeoxycholic acid alleviates secondary injury in the spinal cord via up-regulation of CIBZ gene. Cell Stress Chaperones (2018).
- Tauroursodeoxycholic acid protects rat spinal cord neurons after mechanical injury through regulating neuronal autophagy. Neurosci Lett (2022).
- Injectable Hydrogel Containing Tauroursodeoxycholic Acid for Anti-neuroinflammatory Therapy After Spinal Cord Injury in Rats. Mol Neurobiol (2020).
- Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis. N Engl J Med (2020).
- Bile acid metabolites predict multiple sclerosis progression and supplementation is safe in progressive disease. Med (2025).
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
